Silence Therapeutics Q2 FY26 net loss narrows to $12.3 million; revenue falls to $0 from $224,000
SLN•Expenses decline and cash position
R&D expenses fell 48% to USD 9.1 million on zerlasiran Phase 3 readiness completion in 2025 and lower personnel costs.
G&A expenses edged down to USD 4.7 million from USD 5.1 million; cash and cash equivalents totaled USD 72.1 million at June 30.
Q2 loss narrows as revenue falls to zero
Silence Therapeutics posted a Q2 net loss of USD 12.3 million, narrowing from USD 27.4 million a year earlier; loss per share improved to USD 0.09 from USD 0.19.
Revenue fell to USD 0 from USD 224,000.
Pipeline updates across clinical and preclinical programs
The company completed patient dosing in the Phase 2 SANRECO trial of divesiran in 48 phlebotomy-dependent polycythemia vera patients in June.
Phase 1 results for showed favorable safety with durable, dose-dependent reductions; preclinical programs and remain positioned for potential .
